Step Pharma Appoints Neil Gallagher to Strengthen R&D Leadership
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 01 2026
0mins
Source: Newsfilter
- New Board Member: Step Pharma announces the appointment of Dr. Neil Gallagher as a Non-Executive Director, leveraging over 25 years of clinical development experience in hematology and oncology to support the company's advancement of dencatistat across three clinical programs targeting essential thrombocythemia, lymphoma, and solid tumors.
- Enhanced R&D Leadership: Neil's previous roles at major pharmaceutical companies, including Amgen and AbbVie, where he successfully led multiple innovative oncology therapies through regulatory approvals, will be invaluable in navigating complex development projects for Step Pharma.
- Innovative Treatment Strategy: Neil emphasizes Step Pharma's 'pipeline in a product' strategy, indicating the company's efficiency in clinical development, which is expected to deliver new treatment options for multiple indications with high unmet needs, thereby enhancing the company's competitive position in the market.
- Industry Impact: With a mission to transform cancer treatment through targeted therapies, Neil's addition to the board will further solidify Step Pharma's global leadership in CTPS1 inhibition, driving the development of safe and effective treatment solutions to meet the urgent needs of patients with blood cancers and solid tumors.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy FHTX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on FHTX
Wall Street analysts forecast FHTX stock price to rise
9 Analyst Rating
9 Buy
0 Hold
0 Sell
Strong Buy
Current: 5.050
Low
9.00
Averages
11.38
High
14.00
Current: 5.050
Low
9.00
Averages
11.38
High
14.00
About FHTX
Foghorn Therapeutics Inc. is a clinical-stage, precision therapeutics biotechnology company. The Company is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Control platform, it is systematically studying, identifying and validating potential drug targets within the chromatin regulatory system. The Company is also developing multiple product candidates in oncology. The Gene Traffic Control platform provides an integrated and mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing to identify, validate and potentially drug targets within this system. Its platform enables to produce components of the chromatin regulatory system at scale, thereby allowing to identify these genetic dependencies, understand their mechanism and target their vulnerabilities.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Step Pharma Appoints Neil Gallagher to Strengthen R&D Leadership
- New Board Member: Step Pharma announces the appointment of Dr. Neil Gallagher as a Non-Executive Director, leveraging over 25 years of clinical development experience in hematology and oncology to support the company's advancement of dencatistat across three clinical programs targeting essential thrombocythemia, lymphoma, and solid tumors.
- Enhanced R&D Leadership: Neil's previous roles at major pharmaceutical companies, including Amgen and AbbVie, where he successfully led multiple innovative oncology therapies through regulatory approvals, will be invaluable in navigating complex development projects for Step Pharma.
- Innovative Treatment Strategy: Neil emphasizes Step Pharma's 'pipeline in a product' strategy, indicating the company's efficiency in clinical development, which is expected to deliver new treatment options for multiple indications with high unmet needs, thereby enhancing the company's competitive position in the market.
- Industry Impact: With a mission to transform cancer treatment through targeted therapies, Neil's addition to the board will further solidify Step Pharma's global leadership in CTPS1 inhibition, driving the development of safe and effective treatment solutions to meet the urgent needs of patients with blood cancers and solid tumors.
See More
Cancer Research Enters a New Phase with DDR Inhibitors
- Market Potential: In 2025, global sales of DNA Damage Response inhibitors (DDRi) exceeded $7 billion, with projections indicating that the oncology, diagnostics, and precision medicine markets will reach approximately $750 billion by 2030, highlighting rapid growth potential in this sector.
- Unique Technological Advantage: Onco-Innovations holds exclusive global rights to PNKP inhibitors, and its development of ONC010 nanoparticle encapsulation technology has shown significant biological rationale in treating various cancers, particularly solid tumors.
- Significant Preclinical Results: In mouse models, ONC010 extended median survival from 23 days to 60 days in PTEN-deficient colorectal cancer, demonstrating its efficacy in tumor growth inhibition and a favorable safety profile.
- Comprehensive IP Protection: Onco-Innovations' intellectual property portfolio covers core PNKP inhibitor molecules, nanoparticle delivery science, and synthetic lethality applications, creating a strong competitive moat that secures its leading position in the emerging market.
See More
Foghorn Therapeutics to Participate in Goldman Sachs Healthcare Conference
- Goldman Sachs Conference Participation: Foghorn Therapeutics will participate in the 47th Annual Goldman Sachs Global Healthcare Conference on June 9, 2026, showcasing its innovative drug development in oncology, which is expected to attract investor attention and enhance the company's visibility.
- Management Presentation: CEO Adrian Gottschalk will present at the conference, sharing advancements in the Gene Traffic Control platform aimed at treating serious diseases by correcting abnormal gene expression, potentially sparking market interest in its product pipeline.
- One-on-One Meetings: Management will also engage in one-on-one meetings, providing potential investors with an opportunity to gain deeper insights into the company's strategy and drug candidates, which may facilitate future financing and collaborations.
- Webcast Availability: The conference webcast will be accessible on the company's investor section of the website and available for 90 days, enhancing transparency and attracting more investors interested in its R&D progress.
See More
Foghorn Therapeutics Reports Missed Earnings and Revenue Expectations
- Disappointing Earnings: Foghorn Therapeutics reported a FY GAAP EPS of -$1.18, missing expectations by $0.08, indicating ongoing challenges in profitability that could undermine investor confidence.
- Weak Revenue Growth: The company generated $30.91 million in revenue, a 36.8% year-over-year increase, yet it fell short of the $31.02 million forecast, reflecting intensified market competition and underperformance in product sales, which may pressure future growth.
- Strong Cash Position: As of December 31, 2025, Foghorn had $158.9 million in cash, cash equivalents, and marketable securities, providing a cash runway into the first half of 2028, ensuring funding for ongoing R&D efforts.
- Uncertain Market Outlook: Despite a solid cash position, the dual misses in earnings and revenue may raise concerns about the company's future growth potential, prompting investors to closely monitor subsequent strategic adjustments and market reactions.
See More
Foghorn Therapeutics Appoints New CFO
- New CFO Appointment: Foghorn Therapeutics announced that Ryan Maynard will join as CFO effective February 23, 2026, bringing over 25 years of executive experience in biopharma and healthcare technology, which is expected to enhance the company's financial management.
- Strong Financing Background: Maynard has raised over $1 billion in public and private financings throughout his career, a capability that will likely bolster Foghorn's financial flexibility and market competitiveness in future capital operations.
- Impact of Previous Role: Prior to joining Foghorn, Maynard served as CFO of Cara Therapeutics, and his performance in that role is expected to provide valuable experience that could accelerate the implementation of the company's financial strategies.
- Market Reaction: Although executive changes are typically viewed as positive signals, Foghorn Therapeutics' shares fell by 1.72%, reflecting a cautious market attitude towards this appointment, which may impact investor confidence.
See More
Foghorn Therapeutics to Participate in Biotech Summit
- Summit Participation: Foghorn Therapeutics will participate in the Guggenheim Emerging Outlook Biotech Summit on February 11-12, 2026, in New York, showcasing its innovative drug development in oncology.
- Management Presentation: CEO Adrian Gottschalk is scheduled to present on February 11 at 3:00 PM EST, sharing the latest advancements in the company's gene expression correction efforts, which is expected to attract investor interest.
- Webcast Availability: The presentation will be webcasted under the 'Events & Presentations' section of the company's website and will be available for replay for 30 days, enhancing investor engagement.
- R&D Platform: Foghorn's Gene Traffic Control® platform focuses on developing drug candidates targeting genetically determined dependencies, aiming to drive therapeutic innovation in oncology with significant market potential.
See More
Step Pharma Appoints Neil Gallagher to Strengthen R&D Leadership
- New Board Member: Step Pharma announces the appointment of Dr. Neil Gallagher as a Non-Executive Director, leveraging over 25 years of clinical development experience in hematology and oncology to support the company's advancement of dencatistat across three clinical programs targeting essential thrombocythemia, lymphoma, and solid tumors.
- Enhanced R&D Leadership: Neil's previous roles at major pharmaceutical companies, including Amgen and AbbVie, where he successfully led multiple innovative oncology therapies through regulatory approvals, will be invaluable in navigating complex development projects for Step Pharma.
- Innovative Treatment Strategy: Neil emphasizes Step Pharma's 'pipeline in a product' strategy, indicating the company's efficiency in clinical development, which is expected to deliver new treatment options for multiple indications with high unmet needs, thereby enhancing the company's competitive position in the market.
- Industry Impact: With a mission to transform cancer treatment through targeted therapies, Neil's addition to the board will further solidify Step Pharma's global leadership in CTPS1 inhibition, driving the development of safe and effective treatment solutions to meet the urgent needs of patients with blood cancers and solid tumors.
See More
Cancer Research Enters a New Phase with DDR Inhibitors
- Market Potential: In 2025, global sales of DNA Damage Response inhibitors (DDRi) exceeded $7 billion, with projections indicating that the oncology, diagnostics, and precision medicine markets will reach approximately $750 billion by 2030, highlighting rapid growth potential in this sector.
- Unique Technological Advantage: Onco-Innovations holds exclusive global rights to PNKP inhibitors, and its development of ONC010 nanoparticle encapsulation technology has shown significant biological rationale in treating various cancers, particularly solid tumors.
- Significant Preclinical Results: In mouse models, ONC010 extended median survival from 23 days to 60 days in PTEN-deficient colorectal cancer, demonstrating its efficacy in tumor growth inhibition and a favorable safety profile.
- Comprehensive IP Protection: Onco-Innovations' intellectual property portfolio covers core PNKP inhibitor molecules, nanoparticle delivery science, and synthetic lethality applications, creating a strong competitive moat that secures its leading position in the emerging market.
See More
Foghorn Therapeutics to Participate in Goldman Sachs Healthcare Conference
- Goldman Sachs Conference Participation: Foghorn Therapeutics will participate in the 47th Annual Goldman Sachs Global Healthcare Conference on June 9, 2026, showcasing its innovative drug development in oncology, which is expected to attract investor attention and enhance the company's visibility.
- Management Presentation: CEO Adrian Gottschalk will present at the conference, sharing advancements in the Gene Traffic Control platform aimed at treating serious diseases by correcting abnormal gene expression, potentially sparking market interest in its product pipeline.
- One-on-One Meetings: Management will also engage in one-on-one meetings, providing potential investors with an opportunity to gain deeper insights into the company's strategy and drug candidates, which may facilitate future financing and collaborations.
- Webcast Availability: The conference webcast will be accessible on the company's investor section of the website and available for 90 days, enhancing transparency and attracting more investors interested in its R&D progress.
See More
Foghorn Therapeutics Reports Missed Earnings and Revenue Expectations
- Disappointing Earnings: Foghorn Therapeutics reported a FY GAAP EPS of -$1.18, missing expectations by $0.08, indicating ongoing challenges in profitability that could undermine investor confidence.
- Weak Revenue Growth: The company generated $30.91 million in revenue, a 36.8% year-over-year increase, yet it fell short of the $31.02 million forecast, reflecting intensified market competition and underperformance in product sales, which may pressure future growth.
- Strong Cash Position: As of December 31, 2025, Foghorn had $158.9 million in cash, cash equivalents, and marketable securities, providing a cash runway into the first half of 2028, ensuring funding for ongoing R&D efforts.
- Uncertain Market Outlook: Despite a solid cash position, the dual misses in earnings and revenue may raise concerns about the company's future growth potential, prompting investors to closely monitor subsequent strategic adjustments and market reactions.
See More
Foghorn Therapeutics Appoints New CFO
- New CFO Appointment: Foghorn Therapeutics announced that Ryan Maynard will join as CFO effective February 23, 2026, bringing over 25 years of executive experience in biopharma and healthcare technology, which is expected to enhance the company's financial management.
- Strong Financing Background: Maynard has raised over $1 billion in public and private financings throughout his career, a capability that will likely bolster Foghorn's financial flexibility and market competitiveness in future capital operations.
- Impact of Previous Role: Prior to joining Foghorn, Maynard served as CFO of Cara Therapeutics, and his performance in that role is expected to provide valuable experience that could accelerate the implementation of the company's financial strategies.
- Market Reaction: Although executive changes are typically viewed as positive signals, Foghorn Therapeutics' shares fell by 1.72%, reflecting a cautious market attitude towards this appointment, which may impact investor confidence.
See More
Foghorn Therapeutics to Participate in Biotech Summit
- Summit Participation: Foghorn Therapeutics will participate in the Guggenheim Emerging Outlook Biotech Summit on February 11-12, 2026, in New York, showcasing its innovative drug development in oncology.
- Management Presentation: CEO Adrian Gottschalk is scheduled to present on February 11 at 3:00 PM EST, sharing the latest advancements in the company's gene expression correction efforts, which is expected to attract investor interest.
- Webcast Availability: The presentation will be webcasted under the 'Events & Presentations' section of the company's website and will be available for replay for 30 days, enhancing investor engagement.
- R&D Platform: Foghorn's Gene Traffic Control® platform focuses on developing drug candidates targeting genetically determined dependencies, aiming to drive therapeutic innovation in oncology with significant market potential.
See More
